Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Bevacizumab as a treatment option for radiation necrosis after cranial radiation therapy: a retrospective monocentric analysis.

Bodensohn R, Hadi I, Fleischmann DF, Corradini S, Thon N, Rauch J, Belka C, Niyazi M.

Strahlenther Onkol. 2019 Oct 4. doi: 10.1007/s00066-019-01521-x. [Epub ahead of print]

PMID:
31586230
2.

Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis.

Yonezawa S, Miwa K, Shinoda J, Nomura Y, Asano Y, Nakayama N, Ohe N, Yano H, Iwama T.

J Neurooncol. 2014 Aug;119(1):101-9. doi: 10.1007/s11060-014-1453-y. Epub 2014 May 1.

PMID:
24789256
3.

Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma.

Back M, Gzell CE, Kastelan M, Guo L, Wheeler HR.

Neurooncol Pract. 2015 Mar;2(1):48-53. Epub 2014 Dec 15.

4.

Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients.

Wang Y, Pan L, Sheng X, Mao Y, Yao Y, Wang E, Zhang N, Dai J.

Eur J Med Res. 2012 Aug 23;17:25. doi: 10.1186/2047-783X-17-25.

5.

Targeted intraarterial anti-VEGF therapy for medically refractory radiation necrosis in the brain.

Dashti SR, Spalding A, Kadner RJ, Yao T, Kumar A, Sun DA, LaRocca R.

J Neurosurg Pediatr. 2015 Jan;15(1):20-5. doi: 10.3171/2014.9.PEDS14198.

PMID:
25360851
6.
7.

Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.

Shields LB, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons S, Bourne TD, LaRocca R, Spalding AC.

Radiat Oncol. 2015 Oct 31;10:222. doi: 10.1186/s13014-015-0527-0.

8.

Bevacizumab Use in Refractory Adult Pilocytic Astrocytoma: A Single-Center Case Series.

Carabenciov ID, Bhargav AG, Uhm JH, Ruff MW.

Neurologist. 2019 May;24(3):87-89. doi: 10.1097/NRL.0000000000000227.

PMID:
31045718
9.

Bevacizumab versus bevacizumab and macular grid photocoagulation for macular edema in eyes with non-ischemic branch retinal vein occlusion: results from a prospective randomized study.

Callizo J, Atili A, Striebe NA, Bemme S, Feltgen N, Hoerauf H, Bertelmann T.

Graefes Arch Clin Exp Ophthalmol. 2019 May;257(5):913-920. doi: 10.1007/s00417-018-04223-9. Epub 2019 Jan 4.

PMID:
30610424
10.

Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas.

Liu AK, Macy ME, Foreman NK.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1148-54. doi: 10.1016/j.ijrobp.2008.12.032.

11.

Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.

Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser-Bell S.

Cochrane Database Syst Rev. 2018 Apr 18;4:CD011599. doi: 10.1002/14651858.CD011599.pub2. Review.

12.

Repeat stereotactic radiosurgery as salvage therapy for locally recurrent brain metastases previously treated with radiosurgery.

McKay WH, McTyre ER, Okoukoni C, Alphonse-Sullivan NK, Ruiz J, Munley MT, Qasem S, Lo HW, Xing F, Laxton AW, Tatter SB, Watabe K, Chan MD.

J Neurosurg. 2017 Jul;127(1):148-156. doi: 10.3171/2016.5.JNS153051. Epub 2016 Aug 5.

PMID:
27494815
13.

Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab.

Bumes E, Rzonsa S, Hutterer M, Proescholdt M, Bogdahn U, Riemenschneider MJ, Uhl M, Wendl C, Hau P.

J Neurooncol. 2016 Mar;127(1):191-200. doi: 10.1007/s11060-015-2031-7. Epub 2015 Dec 31.

PMID:
26721240
14.

Optimizing bevacizumab dosing in glioblastoma: less is more.

Ajlan A, Thomas P, Albakr A, Nagpal S, Recht L.

J Neurooncol. 2017 Oct;135(1):99-105. doi: 10.1007/s11060-017-2553-2. Epub 2017 Jun 30.

PMID:
28667595
15.

Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series.

Banks PD, Lasocki A, Lau PKH, Sandhu S, McArthur G, Shackleton M.

Health Sci Rep. 2019 Feb 1;2(3):e115. doi: 10.1002/hsr2.115. eCollection 2019 Mar.

16.

Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.

Levin VA, Chan J, Datta M, Yee JL, Jain RK.

J Neurooncol. 2017 Sep;134(2):325-330. doi: 10.1007/s11060-017-2528-3. Epub 2017 Jun 19.

PMID:
28631191
17.

Ultra-Low-Dose Bevacizumab For Cerebral Radiation Necrosis: A Prospective Phase II Clinical Study.

Zhuang H, Zhuang H, Shi S, Wang Y.

Onco Targets Ther. 2019 Oct 11;12:8447-8453. doi: 10.2147/OTT.S223258. eCollection 2019.

18.

Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study.

Matsuoka A, Maeda O, Mizutani T, Nakano Y, Tsunoda N, Kikumori T, Goto H, Ando Y.

PLoS One. 2016 Dec 19;11(12):e0168707. doi: 10.1371/journal.pone.0168707. eCollection 2016.

19.

A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema.

Wang Y, Wang E, Pan L, Dai J, Zhang N, Wang X, Liu X, Mei G, Sheng X.

J Neurooncol. 2014 Sep;119(2):369-76. doi: 10.1007/s11060-014-1488-0. Epub 2014 May 31.

PMID:
24879376
20.

Bevacizumab: radiation combination produces restricted diffusion on brain MRI.

Hesselink JR, Barkovich MJ, Seibert TM, Farid N, Muller KA, Murphy KT, Kesari S.

CNS Oncol. 2014;3(5):329-35. doi: 10.2217/cns.14.35.

Supplemental Content

Support Center